mRNA Vaccination and Personalized Cancer Therapy

摘要: Nucleic acid vaccines link two prerequisites for success, namely, the delivery of molecularly defined antigens as vaccine targets interest and an inherent adjuvant activity. As compared to DNA-based approaches, in vitro-transcribed messenger RNA (mRNA) is a safer drug format due adjustable, transient expression lack genomic integration. In contrast viral vector vaccines, mRNA vaccination not limited by emergence immune responses against produced backbones. Thus, are particularly attractive cancer immunotherapy which induction clinically meaningful antigen-specific depends on repeated immunization cycles. With favorable platform features such rapid production, easy upscaling, low production costs, immunotherapies rapidly evolving novel oncology. currently utilized clinic either transfecting antigen-presenting cells vitro transferred back patient afterwards or direct vivo application patient. This chapter provides short summary history mRNA-based introduces into design vaccines. The principles various strategies with focus discussed. Finally, review insights preclinical development clinical translation personalized tailored antigen profile individual patients.